top of page

Publications

Host genetic and immune factors drive evasion of HIV-1 pathogenesis in viremic non-progressors

Bayón-Gil Á, Hernández I, Dalmau J, Nieto JC, Urrea V, Garrido-Sanz L, Caratú G, García-Guerrero MC, Gálvez C, Salgado M, Erkizia I, Laguía F, Resa-Infante P, Massanella M, Tonda R, Morata J, Hong KY, Koshy J, Goldman AR, Giron L, Abdel-Mohsen M, Heyn H, Martinez-Picado J, Puertas MC

Med. 2024 Oct 9:S2666-6340(24)00374-X

Exceptional, naturally occurring HIV-1 control: Insight into a functional cure

Salgado M, Migueles SA, Yu XG, Martinez-Picado J.

Med. 2024 Sep 13;5(9):1071-1082

Dual blockade of IL-10 and PD-1 leads to control of HIV viral rebound following analytical treatment interruption

Pereira Ribeiro S, Strongin Z, Soudeyns H, Ten-Caten F, Ghneim K, Pacheco Sanchez G, Xavier de Medeiros G, Del Rio Estrada PM, Pelletier AN, Hoang T, Nguyen K, Harper J, Jean S, Wallace C, Balderas R, Lifson JD, Raghunathan G, Rimmer E, Pastuskova C, Wu G, Micci L, Ribeiro RM, Chan CN, Estes JD, Silvestri G, Gorman DM, Howell BJ, Hazuda DJ, Paiardini M, Sekaly RP

Nat Immunol. 2024 Oct;25(10):1900-1912

Follicular Immune Landscaping Reveals a Distinct Profile of FOXP3(hi)CD4(hi) T Cells in Treated Compared to Untreated HIV

Georgakis S, Orfanakis M, Brenna C, Burgermeister S, Del Rio Estrada PM, González-Navarro M, Torres-Ruiz F, Reyes-Terán G, Avila-Rios S, Luna-Villalobos YA, Chén OY, Pantaleo G, Koup RA, Petrovas C.

Vaccines (Basel). 2024 Aug 12;12(8):912. doi: 10.3390/vaccines12080912.

Understanding early HIV-1 rebound dynamics following antiretroviral therapy interruption: The importance of effector cell expansion

Phan T, Conway JM, Pagane N, Kreig J, Sambaturu N, Iyaniwura S, Li JZ, Ribeiro RM, Ke R, Perelson AS.

PLoS Pathog. 2024 Jul 29;20(7):e1012236. doi: 10.1371/journal.ppat.1012236. eCollection 2024 Jul.

Reprogramming human B cells with custom heavy-chain antibodies

Rogers GL, Huang C, Mathur A, Huang X, Chen HY, Stanten K, Morales H, Chang CH, Kezirian EJ, Cannon PM.

Nat Biomed Eng. 2024 Jul 22. doi: 10.1038/s41551-024-01240-4. Online ahead of print.

Sustained aviremia despite anti-retroviral therapy non-adherence in male children after in utero HIV transmission

Bengu N, Cromhout G, Adland E, Govender K, Herbert N, Lim N, Fillis R, Sprenger K, Vieira V, Kannie S, van Lobenstein J, Chinniah K, Kapongo C, Bhoola R, Krishna M, Mchunu N, Pascucci GR, Cotugno N, Palma P, Tagarro A, Rojo P, Roider J, Garcia-Guerrero MC, Ochsenbauer C, Groll A, Reddy K, Giaquinto C, Rossi P, Hong S, Dong K, Ansari MA, Puertas MC, Ndung'u T, Capparelli E, Lichterfeld M, Martinez-Picado J, Kappes JC, Archary M, Goulder P

Nat Med. 2024 Jun 6; Epub ahead of print.

Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort: a prospective observational cohort study

Salgado M, Gálvez C, Nijhuis M, Kwon M, Cardozo-Ojeda EF, Badiola J, Gorman MJ, Huyveneers LEP, Urrea V, Bandera A, Jensen BO, Vandekerckhove L, Jurado M, Raj K, Schulze Zur Wiesch J, Bailén R, Eberhard JM, Nabergoj M, Hütter G, Saldaña-Moreno R, Oldford S, Barrett L, Ramirez MLM, Garba S, Gupta RK, Revollo B, Ferra-Coll C, Kuball J, Alter G, Sáez-Cirión A, Diez-Martin JL, Duke ER, Schiffer JT, Wensing A, Martinez-Picado J; IciStem Consortium

Lancet HIV. 2024 Jun;11(6):e389-e405

Preclinical development of humanized monoclonal antibodies against CD169 as a broad antiviral therapeutic strategy

Resa-Infante P, Erkizia I, Muñiz-Trabudua X, Linty F, Bentlage AEH, Perez-Zsolt D, Muñoz-Basagoiti J, Raïch-Regué D, Izquierdo-Useros N, Rispens T, Vidarsson G, Martinez-Picado J

Biomed Pharmacother. 2024 Jun;175:116726

Targeting Viral Transcription for HIV Cure Strategies

Izquierdo-Pujol J, Puertas MC, Martinez-Picado J, Morón-López S

Microorganisms. 2024 Apr 8;12(4):752

bottom of page